AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33407631 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of CFE
Number of subjects: 92
Study 33407631 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of CFE
Number of subjects: 92
Study 33407631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 32919517 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (8 g per day, twice daily)
Number of subjects: 90
Study 32919517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32919517 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (for first trimester infections)
Number of subjects: 90
Study 32919517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for first trimester infections)
Number of subjects: 90
Study 36202563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 7038
Study 36202563 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 7038
Study 32472161 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) received additional involuntary, reflexive training
Number of subjects: 77
Study 32472161 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) performed a standard physiotherapy program
Number of subjects: 77
Study 32472161 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EXP and CON) during running
Number of subjects: 77
Study 32899071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy containing bevacizumab (folinic acid, bolus/continuous fluorouracil, and irinotecan)
Number of subjects: 55
Study 32899071 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy containing bevacizumab (modified folinic acid, bolus/continuous fluorouracil, and oxaliplatin)
Number of subjects: 55
Study 35501762 — intervention group
Group type: EXPERIMENTAL
Intervention: KMC by mother and surrogate 3 times a day for up to 4 days, 60 minutes each time
Number of subjects: 70
Study 35501762 — intervention group
Group type: COMPARATOR
Intervention: KMC by mother 3 times a day for up to 4 days, 60 minutes each time
Number of subjects: 70
Study 33664161 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 250
Study 33664161 — intervention group
Group type: COMPARATOR
Intervention: Sham training, no training, standard treatment, or breathing exercises
Number of subjects: 250
Study 33487789 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session therapy
Number of subjects: 40
Study 33487789 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-session therapy
Number of subjects: 40
Study 33052760 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 2 weeks and apatinib 250 mg once per day
Number of subjects: 45
Study 33052760 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 45
Study 34181823 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary evaluation (surgeon + physical therapist)
Number of subjects: 78
Study 34181823 — intervention group
Group type: COMPARATOR
Intervention: Standard evaluation (surgeon only)
Number of subjects: 78
Study 32947389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) application
Number of subjects: 100
Study 32947389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMC treatment)
Number of subjects: 100
Study 36001378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of continued smoking frame
Number of subjects: 99
Study 36001378 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal risks of continued smoking frame
Number of subjects: 99
Study 36001378 — intervention group
Group type: EXPERIMENTAL
Intervention: Losses of not participating frame
Number of subjects: 99
Study 35344476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 23
Study 35344476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 32950645 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT + Variety
Number of subjects: 156
Study 32950645 — intervention group
Group type: COMPARATOR
Intervention: FBT
Number of subjects: 156
Study 33491052 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced step training (IST)
Number of subjects: 100
Study 33491052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip muscle strengthening (HST)
Number of subjects: 100
Study 33491052 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CMB)
Number of subjects: 100
Study 33491052 — intervention group
Group type: COMPARATOR
Intervention: Seated flexibility/relaxation exercises (SFR)
Number of subjects: 100
Study 32800305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 51
Study 32800305 — intervention group
Group type: COMPARATOR
Intervention: Written Exposure Therapy (WET)
Number of subjects: 51
Study 33417663 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 g/kg/day protein plus placebo
Number of subjects: 92
Study 33417663 — intervention group
Group type: COMPARATOR
Intervention: 0.8 g/kg/day protein plus placebo
Number of subjects: 92
Study 33417663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg/day protein plus testosterone enanthate 100 mg weekly
Number of subjects: 92
Study 33417663 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 g/kg/day protein plus testosterone enanthate 100 mg weekly
Number of subjects: 92
Study 32379280 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 28 days) plus Tremelimumab (75 mg every 28 days for the first 4 cycles)
Number of subjects: 180
Study 32379280 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 180
Study 32379280 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Tremelimumab
Number of subjects: 180
Study 32379280 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Tremelimumab in microsatellite stable (MSS) patients
Number of subjects: 180
Study 32379280 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Tremelimumab in MSS patients with plasma TMB of 28 variants per megabase or more
Number of subjects: 180
Study 34278827 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant osimertinib with or without chemotherapy
Number of subjects: 0
Study 34278827 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 33090219 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative intent radical prostatectomy (RP)
Number of subjects: 19684
Study 33090219 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with or without androgen deprivation therapy
Number of subjects: 19684
Study 33090219 — intervention group
Group type: EXPERIMENTAL
Intervention: Score system
Number of subjects: 19684
Study 36480703 — intervention group
Group type: EXPERIMENTAL
Intervention: Group member support
Number of subjects: 120
Study 36480703 — intervention group
Group type: EXPERIMENTAL
Intervention: Group leader support
Number of subjects: 120
Study 36480703 — intervention group
Group type: EXPERIMENTAL
Intervention: Group member and leader support
Number of subjects: 120
Study 33916599 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+SS
Number of subjects: 16
Study 33916599 — intervention group
Group type: COMPARATOR
Intervention: RT only
Number of subjects: 16
Study 35932065 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)
Number of subjects: 197
Study 35932065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 197
Study 35932065 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor glycemic control
Number of subjects: 197
Study 34267689 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 74
Study 34267689 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 74
Study 32997438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockdown period
Number of subjects: 124
Study 32997438 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Number of subjects: 124
Study 35301577 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus RM
Number of subjects: 29
Study 35301577 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture plus RM
Number of subjects: 29
Study 35301577 — intervention group
Group type: COMPARATOR
Intervention: RM alone
Number of subjects: 29
Study 36178948 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher accredited schools (platinum, gold, silver)
Number of subjects: 1454
Study 36178948 — intervention group
Group type: COMPARATOR
Intervention: Lower accredited schools (bronze and below bronze)
Number of subjects: 1454
Study 33268222 — intervention group
Group type: EXPERIMENTAL
Intervention: Local warming (hot pack at 40°C for 5 minutes)
Number of subjects: 35
Study 33268222 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 35
Study 32990807 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning system for amyloid burden estimation
Number of subjects: 121
Study 32990807 — intervention group
Group type: COMPARATOR
Intervention: Visual reading without deep learning system
Number of subjects: 121
Study 32990807 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual reading with deep learning system
Number of subjects: 121
Study 36113984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Game Safety Huddles
Number of subjects: 343
Study 36113984 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 343
Study 34009486 — intervention group
Group type: EXPERIMENTAL
Intervention: iRARC
Number of subjects: 177
Study 35636205 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid sparing (OS) protocol (patient education and perioperative multimodal analgesia)
Number of subjects: 129
Study 35636205 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-opioid (ZO) protocol (same as OS but no opioid prescriptions at discharge)
Number of subjects: 129
Study 35636205 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 129
Study 34341423 — intervention group
Group type: EXPERIMENTAL
Intervention: High DHM group (D group) with 359.12 mg/g DHM
Number of subjects: 0
Study 34341423 — intervention group
Group type: COMPARATOR
Intervention: Low DHM group (B group) with 210.31 mg/g DHM
Number of subjects: 0
Study 32118656 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-Infrared Spectroscopy (NIRS)
Number of subjects: 9
Study 32118656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory technique
Number of subjects: 9
Study 32118656 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS and Ventilatory techniques
Number of subjects: 9
Study 32118656 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 9
Study 33231131 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfect biomarker assay
Number of subjects: 0
Study 33231131 — intervention group
Group type: EXPERIMENTAL
Intervention: Imperfect biomarker assay (sensitivity = 0.8, specificity = 0.7)
Number of subjects: 0
Study 33231131 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-positive prevalence P(B = 1) = 0.2 and 0.5
Number of subjects: 0
Study 32660725 — intervention group
Group type: EXPERIMENTAL
Intervention: D&C plus ACP gel
Number of subjects: 131
Study 32660725 — intervention group
Group type: COMPARATOR
Intervention: D&C alone
Number of subjects: 131
Study 35814185 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-kHz spinal cord stimulation (SCS) + conventional medical management (CMM)
Number of subjects: 216
Study 35814185 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 216
Study 35312948 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (TAPB) with 30 ml 0.33% ropivacaine and dexmedetomidine 1 μg kg−1
Number of subjects: 225
Study 35312948 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB) with 30 ml 0.33% ropivacaine and dexmedetomidine 1 μg kg−1
Number of subjects: 225
Study 35312948 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with 30 ml 0.9% saline
Number of subjects: 225
Study 33076762 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Choices at Work programme (HCWP)
Number of subjects: 137
Study 33349288 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 515
Study 33349288 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 515
Study 32965715 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP Group)
Number of subjects: 80
Study 32965715 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC Group)
Number of subjects: 80
Study 34465672 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (group B)
Number of subjects: 30
Study 34465672 — intervention group
Group type: COMPARATOR
Intervention: Bicycle ergometer (group A)
Number of subjects: 30
Study 33912695 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard systemic therapy with local ablative radiotherapy
Number of subjects: 100
Study 33912695 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic therapy
Number of subjects: 100
Study 35462028 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over Broca's area
Number of subjects: 15
Study 35462028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over Broca's area
Number of subjects: 15
Study 35462028 — intervention group
Group type: COMPARATOR
Intervention: Sham/placebo control condition
Number of subjects: 15
Study 33206263 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral treatment (ART) initiation irrespective of CD4 count
Number of subjects: 182
Study 33206263 — intervention group
Group type: COMPARATOR
Intervention: Control arm (ART initiation following national guidelines)
Number of subjects: 182
Study 32378975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral neuromuscular electrical stimulation (NMES; 5 days/wk) to quadriceps muscles for 8 weeks
Number of subjects: 22
Study 32378975 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 33159573 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized heat therapy (heat pads applied for 8 hours/day, 5 days/week on one randomly selected calf)
Number of subjects: 15
Study 33081444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten for children (1 tablet 3 times a day)
Number of subjects: 240
Study 33081444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet 3 times a day)
Number of subjects: 240
Study 33081444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten for children
Number of subjects: 240
Study 33081444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 33906814 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion training
Number of subjects: 30
Study 33906814 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 33710154 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 M STS gel
Number of subjects: 12
Study 33710154 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 12
Study 32007430 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shockwave therapy (LiESWT) combined with tadalafil (5 mg/day)
Number of subjects: 92
Study 32007430 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil (5 mg/day) alone
Number of subjects: 92
Study 35196426 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseizure medications plus standard care
Number of subjects: 172
Study 35196426 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 172
Study 35278695 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (pharmaceutical or electrical cardioversion)
Number of subjects: 199
Study 35278695 — intervention group
Group type: COMPARATOR
Intervention: Rate control (b-blocker, digoxin, calcium channel blockers)
Number of subjects: 199
Study 33636987 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill for prevention of cardiovascular disease
Number of subjects: 0
Study 32179526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine (DP) + single low dose of primaquine (SLDPQ; 0.25 mg/kg)
Number of subjects: 109
Study 32179526 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin‐piperaquine (DP)
Number of subjects: 109
Study 35915241 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid therapy
Number of subjects: 0
Study 35915241 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C
Number of subjects: 0
Study 32746734 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR experience
Number of subjects: 82
Study 32746734 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR experience after control treatment
Number of subjects: 82
Study 32746734 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesia
Number of subjects: 82
Study 32746734 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction with VR treatment
Number of subjects: 82
Study 36002594 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified coronally advanced tunnel (MCAT) and connective tissue graft (CTG) with enamel matrix derivative (EMD)
Number of subjects: 24
Study 36002594 — intervention group
Group type: COMPARATOR
Intervention: Modified coronally advanced tunnel (MCAT) and connective tissue graft (CTG) without enamel matrix derivative (EMD)
Number of subjects: 24
Study 36002594 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified coronally advanced tunnel (MCAT) and connective tissue graft (CTG) with EMD
Number of subjects: 24
Study 36002594 — intervention group
Group type: COMPARATOR
Intervention: Modified coronally advanced tunnel (MCAT) and connective tissue graft (CTG) without EMD
Number of subjects: 24
Study 33196866 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiation therapy (RT)
Number of subjects: 64
Study 33196866 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of pain response
Number of subjects: 64
Study 32306154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophic (HYP) strength loading (5 sets with 10 repetitions at 80% of 1RM)
Number of subjects: 12
Study 32306154 — intervention group
Group type: COMPARATOR
Intervention: Maximal (MAX) strength loading (15 sets with 1RM)
Number of subjects: 12
Study 35296994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus Bevacizumab
Number of subjects: 0
Study 35296994 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 35296994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus Bevacizumab (7.5 mg/kg dose of Bevacizumab)
Number of subjects: 0
Study 34319577 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor assessment frequency under PD-dominant PFS condition
Number of subjects: 0
Study 34319577 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor assessment frequency under death-competitive PFS condition
Number of subjects: 0
Study 32427814 — intervention group
Group type: EXPERIMENTAL
Intervention: RUST system
Number of subjects: 45
Study 32427814 — intervention group
Group type: EXPERIMENTAL
Intervention: mRUST system
Number of subjects: 45
Study 35684003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Carica papaya and Morinda citrifolia (28g twice per day for 20 days)
Number of subjects: 188
Study 35684003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 35684003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Carica papaya and Morinda citrifolia
Number of subjects: 188
Study 32673417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 821
Study 32673417 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (10 mg once a day)
Number of subjects: 821
Study 32673417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 821
Study 32673417 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 821
Study 35686365 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE+EM 24 h
Number of subjects: 3
Study 35686365 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE+EM 48 h
Number of subjects: 3
Study 35686365 — intervention group
Group type: COMPARATOR
Intervention: CSE
Number of subjects: 3
Study 33919503 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 0
Study 33919503 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 0
Study 32091548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (2800 IU/d)
Number of subjects: 623
Study 32091548 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose vitamin D supplementation (400 IU/d)
Number of subjects: 623
Study 35040926 — intervention group
Group type: EXPERIMENTAL
Intervention: MedSafer software deprescribing reports
Number of subjects: 5698
Study 35040926 — intervention group
Group type: COMPARATOR
Intervention: Usual care (medication reconciliation)
Number of subjects: 5698
Study 32498561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP control (Group A)
Number of subjects: 73
Study 32498561 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard BP control (Group B)
Number of subjects: 73
Study 32498561 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor BP control (Group C)
Number of subjects: 73
Study 32498561 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 73
Study 34059552 — intervention group
Group type: EXPERIMENTAL
Intervention: MRTP claim for heated tobacco products (HTPs), n=1190
Number of subjects: 2354
Study 34059552 — intervention group
Group type: COMPARATOR
Intervention: No claim for heated tobacco products (HTPs), n=1164
Number of subjects: 2354
Study 33361498 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency meal consumption (six times a day)
Number of subjects: 10
Study 33361498 — intervention group
Group type: COMPARATOR
Intervention: Regular frequency meal consumption (three times a day)
Number of subjects: 10
Study 32446880 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment focusing on lifestyle recommendations (ST)
Number of subjects: 174